A Pilot Cross-Over Study to Evaluate Human Oral Bioavailability of BCM-95CG (Biocurcumax), A Novel Bioenhanced Preparation of Curcumin
TLDR
Reconstituting curcumin with the non-curcuminoid components of turmeric has been found to increase the bioavailability substantially and BCM-95®CG, a patented formulation, has potential for widespread application for various chronic diseases.Abstract:
Curcumin, the bioactive component of turmeric, Curcuma longa has an exceptionally wide spectrum of activities including antioxidant, anti-inflammatory and anti-cancer properties, and is currently under different phases of clinical trials for various types of soft tissue cancers. However, although in vitro and animal studies have shown anticancer activities of curcumin for virtually all types of human cancers, its poor bioavailability in the human body has severely limited its application to these diseases. Methods to increase its oral bioavailability are a subject of intense current research. Reconstituting curcumin with the non-curcuminoid components of turmeric has been found to increase the bioavailability substantially. In the present clinical study to determine the bioavailability of curcuminoids, a patented formulation, BCM-95((R))CG was tested on human volunteer group. Normal curcumin was used in the control group. Curcumin content in blood was estimated at periodical intervals. After a washout period of two weeks the control group and drug group were crossed over BCM-95((R))CG and curcumin, respectively. It was also compared with a combination of curcumin-lecithin-piperine which was earlier shown to provide enhanced bioavailability. The results of the study indicate that the relative bioavailability of BCM-95((R))CG (Biocurcumax) was about 6.93-fold compared to normal curcumin and about 6.3-fold compared to curcumin-lecithin-piperine formula. BCM-95((R))CG thus, has potential for widespread application for various chronic diseases.read more
Citations
More filters
Journal ArticleDOI
Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials
TL;DR: Curcumin has shown protection against hepatic conditions, chronic arsenic exposure, and alcohol intoxication, and dose-escalating studies have indicated the safety of curcumin at doses as high as 12 g/day over 3 months.
Journal ArticleDOI
Curcumin and Cancer
TL;DR: A review of the cell signaling pathways involved in cancer development and proliferation, and which are targeted by curcumin, suggests this polyphenol compound, alone or combined with other agents, could represent an effective drug for cancer therapy.
Journal ArticleDOI
The Molecular Basis for the Pharmacokinetics and Pharmacodynamics of Curcumin and Its Metabolites in Relation to Cancer
TL;DR: This review addresses the oncopharmacological properties of curcumin at the molecular level, whereby the phenotypical/biological changes induced in cancer cells upon completion of theCurcumin-triggered signaling cascade(s) are addressed in the framework of the hallmarks of cancer.
Journal ArticleDOI
A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis.
Binu Chandran,Ajay Goel +1 more
TL;DR: This study provides the first evidence for the safety and superiority of curcumin treatment in patients with active rheumatoid arthritis, and highlights the need for future large‐scale trials to validate these findings in Patients with RA and other arthritic conditions.
Journal ArticleDOI
Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study.
John M. Ringman,Sally A. Frautschy,Edmond Teng,Aynun N. Begum,Jenny Bardens,Maryam Beigi,Karen H. Gylys,Vladimir Badmaev,Dennis D. Heath,Liana G. Apostolova,Verna Porter,Zeba Vanek,Gad A. Marshall,Gerhard Hellemann,Catherine A. Sugar,Donna Masterman,Thomas J. Montine,Jeffrey L. Cummings,Greg M. Cole +18 more
TL;DR: Curcumin was generally well-tolerated although three subjects on curcumin withdrew due to gastrointestinal symptoms, and preliminary data suggest limited bioavailability of this compound.
References
More filters
Journal Article
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions.
Ann-Lii Cheng,Hsu Ch,Lin Jk,Hsu Mm,Yunn-Fang Ho,Shen Ts,Ko Jy,Lin Jt,Bor-Ru Lin,Ming-Shiang W,Yu Hs,Shiou-Hwa Jee,Chen Gs,Chen Tm,Chi-An Chen,Lai Mk,Yeong-Shiau Pu,Min-Hsiung Pan,Wang Yj,Tsai Cc,Hsieh Cy +20 more
TL;DR: It is demonstrated that curcumin is not toxic to humans up to 8,000 mg/day when taken by mouth for 3 months and a biologic effect ofCurcumin in the chemoprevention of cancer is suggested.
Journal ArticleDOI
Molecular targets of dietary agents for prevention and therapy of cancer
TL;DR: Evidence is presented that numerous agents identified from fruits and vegetables can interfere with several cell-signaling pathways and the active principle identified in fruit and vegetables and the molecular targets modulated may be the basis for how these dietary agents not only prevent but also treat cancer and other diseases.
Journal ArticleDOI
Influence of Piperine on the Pharmacokinetics of Curcumin in Animals and Human Volunteers
TL;DR: The study shows that in the dosages used, piperine enhances the serum concentration, extent of absorption and bioavailability of curcumin in both rats and humans with no adverse effects.
Journal ArticleDOI
Curcumin: The story so far
TL;DR: Sufficient data currently exist to advocate phase II clinical evaluation of oral curcumin in patients with invasive malignancy or pre-invasive lesions of the gastrointestinal tract, particularly the colon and rectum.
Journal ArticleDOI
Multiple biological activities of curcumin: a short review.
TL;DR: This review summarizes the most interesting in vitro and in vivo studies on the biological effects of curcumin, the constituent of turmeric, which has been widely studied for its anti-inflammatory, anti-angiogenic,Anti-oxidant, wound healing and anti-cancer effects.